Search
forLearn
5 / 801 resultslearn sesbania grandiflora extract
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn 18β-glycyrrhetinic acid
learn GT20029
research compound made to degrade androgen receptors in scalp
Research
5 / 10 results
research Glycolytic Dysfunction in Granulosa Cells and Its Contribution to Metabolic Dysfunction in Polycystic Ovary Syndrome
Targeting glycolysis may help treat PCOS by improving insulin sensitivity and ovarian function.
research Morroniside regulates hair growth and cycle transition via activation of the Wnt/β-catenin signaling pathway
Morroniside may help hair grow and stay in its growth phase by affecting certain cell signals.
research Multiple readout assay for hormonal (androgenic and antiandrogenic) and cytotoxic activity of plant and fungal extracts based on differential prostate cancer cell line behavior
The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.
research Hidradenitis suppurativa
Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.
research Hospitalists for the NHS
Antiandrogen therapy may help treat hidradenitis suppurativa.
Community Join
5 / 1000+ resultscommunity GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community Estimate of GT20029 on the grey market?
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
community 2-deoxy-D-ribose (2dDR), a sugar molecule, was found to be 80%-90% as effective as minoxidil in promoting hair growth and neovascularization in androgenic alopecia models, showing promise for alopecia treatment.
2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.